OphthoCare had developed unique electronic glasses (Liquid Crystal Glasses - LCG) which function as an electronic shutter. The device is suitable for treatment of various ocular disorders and nerve stimulation applications.

The first product available, can be used for treating Amblyopia (lazy eye) in children. This application had been tested in a successfully clinical study performed at three medical centers in Israel. The study had showed excellent efficacy, acceptance by children and parents (high compliance) and no side effects.

Pre-clinical studies on additional wide variety of applications are ongoing.

Company products are based on novel IP, backed by full licensing of relevant prior art. Strong in house-research and development capabilities facilitates R&D.

• Backed by leading Ophthalmologists
• FDA approved (510K)
• Ready for large scale production and world-wide sales by fourth quarter 2007
• Continuous R&D towards new applications

The project is backed by highly experienced entrepreneurs in the medical device area:

Rafi Herzog – (B.Sc, MBA), CEO and President
Yossi Gross – (B.Sc), Technical Director,
Dr. Omry Ben Ezra – (MD), Medical Director

Medical Advisory Board is headed by Prof. David Ben Ezra, Director, Pediatric Ophthalmology Unit, Hadassah Hospital, Jerusalem, Israel

OphthoCare operates under the Maayan Ventures umbrella in Beer Sheva, Israel.